# OnCo record adc-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/adc-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "adc-therapeutics" ;
  schema:name "ADC Therapeutics"@en ;
  schema:alternateName "ADC Therapeutics S.A."@en, "ADC Therapeutics SA"@en ;
  schema:description "ADC Therapeutics, based in Lausanne, developed Zynlonta (loncastuximab tesirine), an antibody-drug conjugate built on its pyrrolobenzodiazepine payload platform and approved in diffuse large B-cell lymphoma. It is now switching to exatecan-based payloads, so its future rests on changing platform while staying independent."@en ;
  schema:url <https://onco.cc/companies/adc-therapeutics/>, <https://adctherapeutics.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://adctherapeutics.com> ;
  schema:addressCountry "CH" ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:drugs <https://onco.cc/drugs/zynlonta/> ;
  onco:trials <https://onco.cc/trials/nct04384484/> .